2 active not recruiting, 2 completed, 2 terminated, 1 recruiting. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Completed 2, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow Ritlecitinib: new trials by email Literature Review of Ritlecitinib trials Research Report on Ritlecitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria Ritlecitinib - Chronic Spontaneous Urticaria, CSU | Phase 2 | Withdrawn | Ahuva D Cices | 2025-12-31 | 2025-12-09 | |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Ritlecitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Pfizer | 128 | 2025-11-13 | 2026-10-20 |
| Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy Ritlecitinib - Keloid | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 30 | 2024-08-13 | 2026-09-01 |
| Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 78 | 2023-10-19 | 2026-09-02 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission Ritlecitinib, Placebo, Gluten - Celiac Disease | Phase 2 | Completed | Massachusetts General Hospital | 62 | 2023-03-01 | 2026-10-30 |
| Ritlecitinib for Cicatricial Alopecia PF-06651600 - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 50 | 2022-12-15 | 2026-07-15 |
| PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA PF-06651600, Placebo - Alopecia Areata | Phase 2 | Terminated | Pfizer | 71 | 2020-09-15 | 2025-07-11 |
Alopecia (2) · Alopecia Areata (1) · Alopecia universalis (1) · Celiac Disease (1) · Chronic Urticaria (1) · Diabetes Mellitus, Type 1 (1) · Hidradenitis Suppurativa (1) · Keloid (1) · Lichen Planus (1) · Mycosis Fungoides (1) · Sezary Syndrome (1)
Icahn School of Medicine at Mount Sinai (2) · Pfizer (2) · Ahuva D Cices (1) · Emma Guttman (1) · Massachusetts General Hospital (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
United States (8) · Canada (3) · Australia (2) · Poland (2) · Germany (1) · Greece (1) · Spain (1)
Ahuva Cices, MD (1) · Emma Guttman, MD, PhD (1) · Emma Guttman-Yassky, MD, PhD (1) · Maureen Leonard, MD (1) · Patrick Brunner, MD (1)
PMID 38263353, PMID 41917311, PMID 42481842
2025 (1)